Unit Trusts

UIT

Nuveen ARK Genomic Healthcare and Biotech Portfolio, 2Q 2016



Product Performance as of 9/21/2017

 Year To DateSince DepositThree MonthSix Month
Distributions Reinvested
With Transaction Sales Charges36.91 %43.60 %2.81 %22.94 %
Without Transaction Sales Charges40.34 %47.21 %5.39 %26.03 %
Distribution in Cash
With Transaction Sales Charges36.91 %41.96 %2.81 %22.94 %
Without Transaction Sales Charges40.34 %45.52 %5.39 %26.03 %

Returns With Transactional Sales Charge reflect the maximum transactional sales charge that would be payable by an investor upon sale or redemption of units at the end of the applicable period(s). The transactional sales charge includes any initial or deferred sales charges other than the creation and development fee. These returns do not reflect any creation and development fee prior to collection (generally the close of the initial offering period). Any creation and development fee is reflected in the returns as of the time of payment by a trust.

Returns Without Transactional Sales Charge do not reflect any transactional sales charge and do not reflect any creation and development fee prior to collection (generally the close of the initial offering period). Any creation and development fee is reflected in the returns as of the time of payment by a trust.

Returns are cumulative total returns (not annualized) unless labeled as average annual returns. Distribution Received in Cash returns reflect trust expenses as incurred and assume income and principal distributions are recognized on the ex-dividend date and paid out in cash on the payable date. Distributions Reinvested returns reflect trust expenses as incurred and assume income and principal distributions are recognized on the ex-dividend date and reinvested on the reinvestment date.

Past performance is no indication of future results. Investment return and principal value will fluctuate with changes in market conditions. Units when redeemed may be worth more or less than their original cost.

All returns are historical and do not represent potential future performance. A trust’s performance, especially for short time periods, should not be the sole factor in making your investment decision.

This material is not intended to be a recommendation or investment advice, does not constitute a solicitation to buy or sell securities, and is not provided in a fiduciary capacity. The information provided does not take into account the specific objectives or circumstances of any particular investor, or suggest any specific course of action. Investment decisions should be made based on an investor’s objectives and circumstances and in consultation with his or her advisors.

Risk Considerations
Investing involves risk; principal loss is possible. This Trust is unmanaged and there is no guarantee that the Trust’s investment objectives will be achieved. There is no assurance that common stocks will make dividend payments. Dividends are paid only if declared by an issuer's board of directors and the amount of any dividend may vary over time. A portfolio concentrated in a single market sector may present more risk than a portfolio broadly diversified over several sectors. This Trust is concentrated in the healthcare sector. There are certain risks specific to healthcare companies such as governmental regulation and the risk that a product may never come to pass. Biotechnology companies are subject to government regulation and their valuation can often be based on the potential or actual performance of a limited number of products and can be greatly affected if such products proves to be unsafe, ineffective, or unprofitable. Companies in the pharmaceutical industry can be significantly affected by government approval of products and services, government regulation and reimbursement rates, product liability claims, patent expirations and protection and intense competition. Non-U.S. investments involve additional risks, including currency fluctuation, political and economic instability, lack of liquidity and differing legal and accounting standards. Stocks of small and mid-cap companies are often more volatile than those of larger companies as a result of several factors such as limited trading volumes, products or financial resources, management inexperience and less publicly available information. These and other risk considerations, such as various business, market, and investment risks are described in detail in the Trust’s prospectus.
 
Although this Trust’s life is approximately 15 months, the Trust’s strategy should be considered as part of a long-term investment strategy and investors should consider, in light of their particular financial situations, whether it may be appropriate to invest in successive trust portfolios, if available, subject to the applicable sales charges. There may be tax consequences associated with an investment from one series to the next unless units are purchased in an IRA or other qualified tax-deferred account. Investors should consult their tax advisor.
 
NOT FDIC INSURED - NOT BANK GUARANTEED - MAY LOSE VALUE
 
Nuveen Securities, LLC, a registered broker-dealer, serves as the Trust’s sponsor and Nuveen Fund Advisors, LLC serves as the Trust’s evaluator and supervisor. ARK Investment Management LLC (“ARK”) serves as the portfolio consultant responsible for recommending a portfolio of securities for the Trust and is not affiliated with the Trust’s sponsor or its evaluator and supervisor.
 


Trust Summary

Trust NameNuveen ARK Genomic Healthcare and Biotech Portfolio, 2Q 2016
Series Name2Q 2016
Trust SymbolAHB2Q16
Nasdaq SymbolNVAHBX
Trust StatusTerminated
Initial Offer Date06/22/2016
Termination Date09/21/2017
First Income Record Date12/10/2016
Distibution FrequencySemi-annually
Tax StructureRIC
Liquidation Price1$13.7595
Cash CUSIP67078G100
Reinvest CUSIP67078G118
Fee Cash CUSIP67078G126
Fee Reinvest CUSIP67078G134

1. Represents the value per unit that a unitholder would receive if the unitholder redeemed or sold units. This price is equal to the net asset value per unit plus any remaining organization costs and creation & development fee. This price reflects any remaining non-contingent deferred sales charges payable in connection with a liquidation of units.

Not registered?

Register for access to investment team commentary, detailed portfolio information, and other advisor resources. For instant access, register now.

Your Contacts

Our goal is to deliver lasting value to our clients. For assistance, please call or email our advisor service team or contact your personal Nuveen Service Team.

Log in to nuveen.com to access your personal Nuveen Service Team.

Financial Advisors

800-752-8700
Email

Registered Investment Advisors

800-558-4487

Account Access

For more information on Mutual Fund Vision, FAN Mail, or accessing client accounts, please visit our advisor account access page.

Advisor Access

Investor Access